On May 6, 2025, HC Wainwright & Co. announced an update regarding Biomea Fusion (BMEA, Financial), maintaining their "Buy" rating but significantly lowering the price target. Previously set at $40.00, the new price target stands at $18.00, representing a 55% decrease.
This adjustment was made by analyst Joseph Pantginis, who continues to hold a favorable view of Biomea Fusion's prospects despite the lowered price target. The changes reflect the current market conditions affecting BMEA. The alterations aim to better align expectations with the company's financial trajectory and ongoing developments.
BMEA, listed on the NASDAQ, remains under the "Buy" rating, indicating continued confidence in its potential for future growth. Stakeholders are encouraged to watch for further announcements from HC Wainwright & Co. regarding any potential adjustments or updates in their analysis of Biomea Fusion.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Biomea Fusion Inc (BMEA, Financial) is $21.86 with a high estimate of $54.00 and a low estimate of $3.00. The average target implies an upside of 992.86% from the current price of $2.00. More detailed estimate data can be found on the Biomea Fusion Inc (BMEA) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Biomea Fusion Inc's (BMEA, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
